Ouro Medicines Achieves FDA Orphan Drug Designation for Gamgertamig in Treating Immune Thrombocytopenia Ouro Medicines secures FDA Orphan Drug Designation for Gamgertamig, aimed at treating immune thrombocytopenia. This marks a significant milestone in its development process.

Ouro Medicines Achieves FDA Orphan Drug Designation for Gamgertamig in Treating Immune Thrombocytopenia #United_States #South_San_Francisco #Ouro_Medicines #FDA_Orphan_Drug #Gamgertamig

Precision NeuroMed Achieves Orphan Drug Status for Glioblastoma Treatment Innovations Precision NeuroMed has been awarded the FDA Orphan Drug Designation for its novel glioblastoma treatment, showcasing advancements in drug delivery systems for better patient outcomes.

Precision NeuroMed Achieves Orphan Drug Status for Glioblastoma Treatment Innovations #USA #Redwood_City #Glioblastoma #FDA_Orphan_Drug #Precision_NeuroMed

Hemispherian's GLIX1 Awarded FDA Orphan Drug Status for Malignant Glioma Treatment Hemispherian AS is pleased to announce that the FDA has conferred Orphan Drug Designation to GLIX1, a promising treatment for malignant glioma, enhancing its potential in oncology.

Hemispherian's GLIX1 Awarded FDA Orphan Drug Status for Malignant Glioma Treatment #Norway #Oslo #GLIX1 #Hemispherian #FDA_Orphan_Drug